The completion of the separation is set to occur on
Nasdaq has approved the listing of Mural Oncology's ordinary shares on the Nasdaq Global Market under the stock ticker symbol "MURA" beginning on
The completion of the separation is subject to certain conditions described in the Form 10, including those conditions set forth in a separation agreement to be entered into between Alkermes and Mural Oncology, a form of which is filed as an exhibit to the Form 10.
For more information about the separation, the distribution and Mural Oncology's ordinary shares, refer to the Form 10, which can be viewed at http://www.sec.gov and on the investors section of Alkermes' website at www.alkermes.com.
Following completion of the separation,
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations related to the completion, structure, timing and terms of the planned separation of its oncology business into a new, independent, publicly traded company (Mural Oncology), the distribution of Mural Oncology's ordinary shares, and anticipated public trading markets for Alkermes and Mural Oncology ordinary shares. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: that a condition to the closing of the separation may not be satisfied or waived; that the Company may not complete the separation on the terms or timing currently anticipated or at all; unanticipated developments, costs or difficulties that may delay or otherwise negatively affect the timing or completion of the planned separation or the anticipated trading markets related thereto; and those risks and uncertainties described under the heading "Risk Factors" in the Form 10 filed by Mural Oncology with the
For Media: Katie Joyce +1 781 249 8927
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-effectiveness-of-mural-oncology-form-10-registration-statement-301973376.html